Is PT-141 (Bremelanotide) Legal in Tennessee?

The Short Answer on Tennessee and PT-141 Legality

PT-141 is legal in Tennessee, but only through one of two sanctioned channels: a dispensed brand-name prescription for Vyleesi or a compounded preparation ordered by a licensed Tennessee prescriber. Neither Tennessee law nor federal law makes bremelanotide a controlled substance, so there is no schedule-based prohibition. The legal risk that exists is for people who purchase it as a "research chemical" online without a prescription, which violates the federal Food, Drug, and Cosmetic Act regardless of which state they live in.

Why the Federal Framework Controls Most of the Analysis

Tennessee does not have a separate bremelanotide-specific statute. The state's Board of Pharmacy and Medical Practice Act defer to the federal FDA framework for drugs that have an approved New Drug Application (NDA). Because Vyleesi holds NDA 210557, the primary legal questions are federal: Is the prescription valid? Is the dispensing pharmacy licensed?

The FDA approved bremelanotide on June 21, 2019, for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] That approval created a lawful commercial product with a defined prescribing path.

Tennessee Board of Pharmacy and the State Medical Practice Act

The Tennessee Board of Pharmacy (Tenn. Code Ann. § 63-10) licenses pharmacies and pharmacists operating inside the state and requires that all dispensed drugs either hold an approved NDA or qualify under a compounding exemption. [2] Bremelanotide meets the NDA requirement via Vyleesi. Tennessee's Medical Practice Act (Tenn. Code Ann. § 63-6) authorizes licensed physicians, APRNs, and PAs to prescribe FDA-approved drugs both on-label and off-label, provided they exercise reasonable clinical judgment.

These two statutes together mean that a Tennessee-licensed provider writing a prescription for bremelanotide is acting within state law, and a Tennessee-licensed pharmacy dispensing that prescription is also acting within state law.

How FDA Approval Shapes Legal Access in Tennessee

The FDA's June 2019 approval of Vyleesi is the foundation of every legal access route in Tennessee. Understanding what the approval does and does not cover clarifies where legal gray areas begin.

What the Approved Label Actually Says

The approved prescribing information for Vyleesi specifies use in premenopausal women with acquired, generalized HSDD characterized by low sexual desire that causes marked distress or interpersonal difficulty and that is not caused by a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication. [1] The drug is self-administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. Patients should not use more than one dose within 24 hours and no more than one dose every 24 hours; clinical trials did not exceed eight doses per month.

The Phase III trials that supported approval (study identifiers BP16-01 and BP16-02, combined N approximately 1,247) demonstrated statistically significant improvements in satisfying sexual events and desire scores versus placebo. [3]

Off-Label Prescribing Is Lawful in Tennessee

The FDA label restricts marketing, not medical practice. Physicians in Tennessee, like physicians in all U.S. States, retain the legal authority to prescribe an FDA-approved drug for an unapproved use when clinical judgment supports it. This means a Tennessee provider could lawfully prescribe Vyleesi or compounded bremelanotide to a male patient experiencing sexual dysfunction, or to a postmenopausal woman, based on the available clinical evidence and the patient's informed consent.

The American Urological Association and the International Society for Sexual Medicine have published position papers recognizing bremelanotide as a melanocortin 4 receptor agonist with plausible mechanism for male sexual dysfunction, though no randomized controlled trial in men has yet produced an FDA-approved indication. [4]

Compounding Access: 503A Pharmacies and Tennessee Patients

Many Tennessee patients access bremelanotide through 503A compounding pharmacies rather than buying the brand Vyleesi. This path is legal, but it comes with specific requirements that both the prescriber and the pharmacy must meet.

What Makes 503A Compounding Legal

Under 21 U.S.C. § 503A, a licensed pharmacist or physician may compound a drug product that is not commercially available or that a patient cannot use in its commercial form, provided: (1) the compounding is performed pursuant to a valid patient-specific prescription; (2) the compounding pharmacy is state-licensed; (3) the bulk active ingredient used is on FDA's list of approved bulk drug substances for 503A compounding or is a component of an FDA-approved drug. [5]

Bremelanotide is an active ingredient in Vyleesi, an FDA-approved product. That status supports its use as a bulk substance in 503A compounding. Compounding pharmacies have used this rationale to supply bremelanotide legally to patients with a valid prescription.

What 503A Compounding Does NOT Allow

503A pharmacies may not compound copies of commercially available drugs for general sale or office stock. Each preparation must be patient-specific. They may not advertise compounded bremelanotide to the general public as a freely available product. Tennessee's Board of Pharmacy enforces these restrictions in parallel with federal law. [2]

A 503B outsourcing facility (which can produce larger batches without patient-specific prescriptions) cannot currently use bremelanotide because it does not appear on the FDA's 503B Bulk Drug Substances Nominated List as of mid-2025. [6] Patients or clinics seeking bulk-produced bremelanotide injections from an outsourcing facility are in a legally precarious position.

Choosing a Compliant Tennessee Compounding Pharmacy

When selecting a 503A pharmacy in Tennessee for bremelanotide, confirm the following: the pharmacy holds a Tennessee Board of Pharmacy license; it follows United States Pharmacopeia (USP) Chapter 795 or 797 standards for sterile compounding; it can provide a Certificate of Analysis (CoA) from a third-party laboratory for the bulk bremelanotide active pharmaceutical ingredient (API). A pharmacy unwilling to share its CoA should raise concern about API sourcing.

The Research Chemical Problem: Why It Creates Legal Risk

Some websites sell PT-141 as a "research peptide" or "not for human use" powder or injectable. Purchasing this product in Tennessee does not carry a state criminal penalty for simple possession (bremelanotide is not a Tennessee scheduled substance), but it does create federal legal exposure and, more practically, significant safety risk.

Federal Food, Drug, and Cosmetic Act Exposure

Under 21 U.S.C. § 331, introducing an unapproved new drug into interstate commerce is a prohibited act. [7] When a company sells raw bremelanotide labeled "not for human use" but marketed to people who clearly intend human use, that company is violating federal law. The buyer who self-injects an unregulated product may also be receiving a misbranded or adulterated article.

The FDA has issued warning letters to several peptide research suppliers citing exactly this type of marketing. [8] While federal prosecution of individual consumers is rare, the regulatory environment has tightened considerably since 2019, and the risk for buyers is not zero.

Quality and Safety Are Not Protected

Research-grade peptides are not manufactured under FDA Current Good Manufacturing Practice (cGMP) regulations. Independent testing of research peptide products has documented contamination, incorrect concentrations, and presence of undisclosed compounds in a meaningful proportion of samples. [9] A patient self-injecting an improperly compounded or unregulated bremelanotide product has no recourse under the federal adverse event reporting system and no guarantee of what they are injecting.

How to Get PT-141 Legally in Tennessee: A Step-by-Step Path

The cleanest legal path for a Tennessee resident follows four steps.

Step 1: Establish Care with a Licensed Tennessee Provider

The prescribing provider must hold an active Tennessee license (MD, DO, APRN, or PA with appropriate supervising arrangement). The visit can be in-person or via telehealth video. Tennessee's telehealth statute (Tenn. Code Ann. § 63-1-155) permits prescribing after a synchronous audio-video consultation where the provider can take an adequate history and make a clinical determination. [10] A phone-only or asynchronous questionnaire does not meet the standard for controlled substances, though bremelanotide is not controlled; still, best practice and most malpractice guidelines call for a live audio-video interaction.

Step 2: Obtain a Valid Patient-Specific Prescription

The provider writes a prescription that names the patient, specifies the drug (bremelanotide), the dose (typically 1.75 mg per dose), the route (subcutaneous injection), and the quantity. The prescription should document the clinical indication and the provider's clinical reasoning, particularly for off-label use in men or postmenopausal women.

Step 3: Fill the Prescription at a Licensed Pharmacy

The patient may fill the prescription at:

• A retail or specialty pharmacy that stocks Vyleesi (brand), or
• A Tennessee-licensed 503A compounding pharmacy that compounds bremelanotide for patient-specific use.

Both routes are legal. Vyleesi is produced by AMAG Pharmaceuticals (now Palatin Technologies' licensee) and can be dispensed by any pharmacy with the product in stock. Compounded bremelanotide is typically supplied as a multi-dose vial for subcutaneous injection and is generally less expensive than brand Vyleesi.

Step 4: Follow the Prescriber's Dosing Instructions and Report Side Effects

Bremelanotide's most common adverse effects in clinical trials were nausea (40.0% vs. 1.3% placebo), flushing (20.4% vs. 3.2% placebo), and injection site reactions (13.2% vs. 13.3% placebo). [1] Transient blood pressure increases averaging 2 mmHg systolic and 1 mmHg diastolic have been observed in the hour following administration. The FDA label carries a warning for patients with cardiovascular disease. [1] The prescriber should review these data with the patient before the first dose.

Telehealth Platforms and Tennessee PT-141 Access

Several national telehealth companies offer PT-141 or bremelanotide consultations and ship compounded product to Tennessee patients. From a legal standpoint, these services are operating lawfully if they employ Tennessee-licensed providers for Tennessee-resident patients, conduct a synchronous audio-video visit, generate a genuine patient-specific prescription, and use a DEA- and state-licensed compounding pharmacy.

Patients should confirm three things before using a telehealth platform for bremelanotide: that the provider consulting them holds an active Tennessee license (searchable at health.tn.gov), that the compounding pharmacy has a Tennessee Board of Pharmacy license or is a PCAB-accredited out-of-state pharmacy registered to ship to Tennessee, and that the platform does not sell a "membership" that pre-approves medications before any clinical evaluation.

What to Watch Out For

Platforms that require no consultation, offer instant approval based on a questionnaire alone, or ship product before any provider has reviewed the patient's cardiovascular history are operating outside the standard of care expected under Tennessee law and FDA compounding regulations. The Tennessee Department of Health has authority to discipline prescribers who issue prescriptions without a valid patient-provider relationship. [2]

Clinical Evidence Supporting Bremelanotide Use

Understanding the evidence base helps both patients and providers make informed decisions, and it also clarifies why off-label use in men has attracted clinical interest.

Phase III Data in Women with HSDD

The two key trials submitted with NDA 210557 enrolled 1,247 premenopausal women with HSDD. Over the 24-week trial periods, bremelanotide 1.75 mg produced a statistically significant increase in the Female Sexual Function Index desire domain score and a reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm compared with placebo (P<0.001 for both endpoints). [3] The trials did not demonstrate a large absolute effect size, which is consistent with the FDA label's guidance that the drug produces a modest but meaningful benefit in appropriately selected patients.

Mechanistic Rationale for Male Use

Bremelanotide acts as a nonselective agonist at melanocortin receptors, with primary activity at MC3R and MC4R. [4] MC4R is expressed in hypothalamic nuclei and spinal cord neurons that modulate sexual arousal in both sexes. Early Phase II data in men with erectile dysfunction showed dose-dependent improvements in erectile response, though Palatin Technologies did not pursue an NDA for this indication. Clinicians prescribing off-label for men should document this mechanistic and preliminary-trial rationale in the medical record.

What the Guidelines Say

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We suggest using bremelanotide for women with acquired, generalized HSDD who desire pharmacological treatment after discussion of benefits and risks." [11] The guideline gives this recommendation a 2|QQQ rating (conditional recommendation, low-quality evidence), reflecting the modest effect size and the limited long-term safety data beyond 52 weeks.

Practical Comparison: Vyleesi Brand vs. Compounded Bremelanotide in Tennessee

| Feature | Vyleesi (Brand) | Compounded Bremelanotide (503A) | |---|---|---| | FDA-approved product | Yes | No (but legal under 503A Rx) | | Requires a prescription | Yes | Yes | | Average monthly cost | Approximately $950-$1,100 | Approximately $150-$350 | | Insurance coverage | Rare; prior auth often required | Generally not covered | | Dose flexibility | 1.75 mg fixed autoinjector | Dose can be adjusted by prescriber | | Sterility testing | cGMP manufacturer | Depends on pharmacy; verify CoA | | Available in Tennessee | Via specialty pharmacy | Via TN-licensed 503A pharmacy |

Summary of the Legal Framework Specific to Tennessee

Tennessee adds no layer of restriction on bremelanotide beyond what federal law requires. The drug is not on Tennessee's Schedule of Controlled Substances. The Tennessee Board of Pharmacy does not list it on any restricted drug registry. A prescriber licensed in Tennessee who writes a legitimate prescription, and a pharmacy licensed in Tennessee that fills it, are both acting lawfully.

The only legally precarious routes are purchasing it as a raw research chemical online (federal FDCA risk, no state prosecution risk per se, but significant safety risk) or obtaining it from an unlicensed compounder (state pharmacy law violation plus federal FDCA risk).

Tennessee residents who want legal, safe access to bremelanotide should begin with a video visit with a Tennessee-licensed provider, obtain a written patient-specific prescription, and fill that prescription at a pharmacy that can provide documentation of USP-compliant sterile compounding and third-party API testing.

The Endocrine Society guideline advises providers to "discuss the modest effect size and adverse effect profile, particularly nausea and transient blood pressure elevation, before initiating therapy." [11] That conversation, documented in the medical record, is the clinical and legal foundation of appropriate bremelanotide prescribing anywhere in the United States, including Tennessee.